Gastrointestinal Stromal Tumor (GIST) Therapeutics Market
Market Insights on Gastrointestinal Stromal Tumor (GIST) Therapeutics covering sales outlook, demand forecast & up-to-date key trends
Gastrointestinal Stromal Tumor (GIST) Therapeutics Market by Drug Type, Therapy, End User & Region | Forecast 2023 to 2033
Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Snapshot
The global gastrointestinal stromal tumor (GIST) therapeutics market is expected to garner a market value of US$ 890 Million in 2023 and is expected to accumulate a market value of US$ 1593 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. Growth of the gastrointestinal stromal tumor (GIST) therapeutics market can be attributed to growing prevalence of GIST in the aging population across the globe. The market for gastrointestinal stromal tumor (GIST) therapeutics registered a CAGR of 3.5% in the historical period 2018 to 2022
Gastrointestinal Stromal Tumor (GIST) Therapeutics refers to the medical treatments used to manage GIST, a type of cancer that occurs in the cells of the gastrointestinal tract. The goal of GIST therapeutics is to control or eliminate the cancer cells and reduce symptoms. The treatment options for GIST include surgery, targeted therapy with tyrosine kinase inhibitors (TKIs), radiation therapy, and chemotherapy. The choice of therapy depends on the size, location, and stage of the tumor, as well as the patient's overall health. The goal is to provide the most effective treatment while minimizing side effects.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 890 Million |
|
Anticipated Forecast Value (2033) |
US$ 1593 Million |
|
Projected Growth Rate (2023 to 2033) |
6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Gastrointestinal Stromal Tumor (GIST) Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Gastrointestinal stromal tumor (GIST) therapeutics reflected a value of 3.5% during the historical period, 2018 to 2022.
The Gastrointestinal Stromal Tumor (GIST) Therapeutics Market was growing during the period from 2018 to 2022. The growth was primarily driven by the increasing incidence of gastrointestinal stromal tumors and the approval of new drugs for the treatment of GIST. In addition, the rising awareness about GIST and the availability of advanced therapies are also contributing to the growth of the market. However, the high cost of treatment and the limited number of approved drugs may hinder the growth of the market.
Thus, the market for Gastrointestinal stromal tumor (GIST) therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Gastrointestinal Stromal Tumor (GIST) Therapeutics Market?
Demand for effective therapies driving growth for GIST therapeutics market
The incidence of GIST is increasing worldwide, which is driving the demand for effective treatment options. As GIST is a difficult cancer to treat, there remains a significant unmet medical need for new and effective therapies. Moreover, development of new technologies, such as tyrosine kinase inhibitors (TKIs), has led to improved treatment outcomes for patients with GIST.
Furthermore, increasing awareness about GIST and its treatment options, among healthcare providers and patients, is driving demand for GIST therapeutics. In addition, governments around the world are providing support for cancer research and drug development, which is helping to drive growth in the GIST therapeutics market.
Availability of various treatments creating lucrative opportunities for GIST therapeutics market
As GIST cannot be completely treated with surgery, the dependency on various therapeutics has increased. Moreover, healthcare professionals are suggesting different therapeutics methods that would cater to the condition of the patients.
Surgery: Surgical removal of the tumor is the primary treatment option for localized GISTs.
Imatinib: This is a tyrosine kinase inhibitor (TKI) that targets the KIT and PDGFRA genes that are often mutated in GISTs. Imatinib is the first-line therapy for advanced GISTs.
Sunitinib: This is another TKI that is used as a second-line treatment for patients who have developed resistance to imatinib.
Regorafenib: This is another TKI that is used as a third-line treatment for patients who have become resistant to both imatinib and sunitinib.
Radiation therapy: Radiation therapy may be used in conjunction with surgery or as palliative treatment for GISTs that cannot be surgically removed.
Chemotherapy: Chemotherapy is generally not effective in treating GISTs, but it may be used in combination with other therapies.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Gastrointestinal Stromal Tumor (GIST) Therapeutics Market?
Lengthy approval process and drug resistance restricting market growth
The cost of GIST treatments, especially targeted therapies and other innovative drugs is high. This, in turn, limits access to these treatments for some patients. GIST is a relatively rare type of cancer, which means that the market for GIST therapeutics is smaller compared to other cancer indications.
As patents for GIST treatments expire, generic versions of these drugs may become available, which can decrease the market share and profitability of brand-name treatments. Some patients with GIST may develop resistance to TKIs, which can limit the effectiveness of these treatments over time.
The approval process for new drugs can be lengthy and expensive, and there is always the risk that a new treatment may not be approved by regulatory agencies. Some GIST treatments can cause adverse effects, such as nausea, vomiting, fatigue, and low blood counts, which can impact patient quality of life and limit the use of these treatments. All these factors are hampering the growth of the GIST market.
Region-Wise Insights
Increasing Healthcare Expenditure in North America Gastrointestinal Stromal Tumor (GIST) Therapeutics Market?
Introduction of new and innovative therapies creating lucrative opportunities for GIST therapeutics
The North American market for Gastrointestinal Stromal Tumor (GIST) therapeutics is one of the largest and most mature markets globally, driven by factors such as a large and aging patient population, high levels of healthcare spending, and a strong presence of pharmaceutical companies. The United States is the largest market for GIST therapeutics in North America, accounting for the majority of sales in the region.
In recent years, the North American market for GIST therapeutics has seen steady growth due to the increasing incidence of GIST, the introduction of new and innovative therapies, and growing demand for effective treatments. The availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), has been a major driver of growth in the market, as these drugs have proven to be highly effective in treating GIST. Thus, North America is expected to possess 39% market share for GIST therapeutics market in 2023.
Availability of Targeted Therapies Bolstering Growth of Gastrointestinal Stromal Tumor (GIST) Therapeutics Market in Asia Pacific?
Growing prevalence of GIST in aging population propelling market growth
The Asia Pacific market for gastrointestinal stromal tumor (GIST) therapeutics is a rapidly growing market, driven by factors such as increasing incidence of GIST, rising levels of healthcare spending, and a growing middle-class population. The market is expected to continue to grow in the coming years, driven by factors such as the increasing availability of targeted therapies, such as tyrosine kinase inhibitors (TKIs), and the growing awareness of GIST among healthcare providers and patients.
Despite these challenges, the Asia Pacific market for GIST therapeutics is expected to continue to grow in the coming years, driven by increasing demand for effective treatments, advances in research and development, and improving economic conditions in the region. The market is also likely to benefit from the growing aging population and the increasing incidence of GIST, which are expected to drive demand for GIST treatments in the future. Thus, Asia Pacific is expected to hold 31% market share for GIST therapeutics market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Comprehensive Care for GIST Patients in Hospitals Making them a Go-To Option for GIST Therapeutics Market?
Presence of innovative drugs and technology making hospitals a viable option for treatment of GIST therapeutics
Hospitals have a high level of expertise in treating complex and rare diseases such as GIST, and often have a dedicated team of specialists who are experienced in diagnosing and treating the condition. In addition, hospitals provide comprehensive care for GIST patients, including surgery, chemotherapy, radiation therapy, and targeted therapies such as tyrosine kinase inhibitors (TKIs). Access to the latest technologies and treatments, including innovative drugs and cutting-edge diagnostic and therapeutic tools, which can improve patient outcomes are making hospitals a go-to option for patients suffering frm GIST.
Moreover, strict quality and safety standards ensure that patients receive high-quality care and are protected from medical errors. In addition, hospitals offer the convenience of having all necessary diagnostic and therapeutic services in one location, reducing the need for multiple trips to different healthcare providers. Thus, hospitals are expected to procure 45% market share for GIST therapeutics market in 2023.
Market Competition
Key players in the gastrointestinal stromal tumor (GIST) therapeutics market are Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc, Cogent Biosciences, Inc, Plexxikon Inc, Theseus Pharmaceuticals, Exelixis, Inc, Ipse, Bristol-Myers Squibb and Takeda
- In June 2022, Taiho Pharmaceutical Co., Ltd. announced that it has obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for the oral heat shock protein (HSP) 90 inhibitor Jeselhy® Tablets 40 mg for the indication of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.
- Cogent Biosciences, Inc, another key player in the gastrointestinal stromal tumor (GIST) therapeutics market is focusing on integrating technology to understand the nature of the ailment and innovate medication for the same.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 890 Million |
|
Market Value in 2033 |
US$ 1593 Million |
|
Growth Rate |
CAGR of 6% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Gastrointestinal Stromal Tumor (GIST) Therapeutics Industry Survey
Drug Type:
- Imatinib
- Ripretinib
- Crenolanib
- Regorafenib
- Avapritinib
- Sunitinib
- Entrectinib
- Larotrectinib
Therapy:
- Targeted therapy
- Chemotherapy
- Radiation therapy
End User:
- Hospitals
- Clinics
- Specialized Cancer Treatment Centres
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Frequently Asked Questions
At what rate did the Gastrointestinal stromal tumor (GIST) therapeutics market flourish from 2018-2022?
From 2018-2022, the Gastrointestinal stromal tumor (GIST) therapeutics market grew at a CAGR of 3.5%
What will be the growth rate of the global Gastrointestinal stromal tumor (GIST) therapeutics market during the forecast period?
The global Gastrointestinal stromal tumor (GIST) therapeutics market is expected to grow with a 6% CAGR during 2023 to 2033.
What will be the projected market size of the Gastrointestinal stromal tumor (GIST) therapeutics market by 2033?
As of 2033, the Gastrointestinal stromal tumor (GIST) therapeutics market is expected to reach US$ 1593 Million
Which end user segment is expected to dominate the global Gastrointestinal stromal tumor (GIST) therapeutics market during 2033?
Hospitals are expected to hold 45% of the market share in 2023 for Gastrointestinal stromal tumor (GIST) therapeutics market.
How is the North America Gastrointestinal stromal tumor (GIST) therapeutics market projected to grow in 2033?
North America is expected to possess 39% market share for Gastrointestinal stromal tumor (GIST) therapeutics market in 2023.
How is the Asia Pacific Gastrointestinal stromal tumor (GIST) therapeutics market projected to grow in 2023?
Asia Pacific Gastrointestinal stromal tumor (GIST) therapeutics market size is expected to possess 31% market share in 2023.
Table of Content
1. Executive Summary | Gastrointestinal Stromal Tumor (GIST) Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 5.3.1. Imatinib 5.3.2. Ripretinib 5.3.3. Crenolanib 5.3.4. Regorafenib 5.3.5. Avapritinib 5.3.6. Sunitinib 5.3.7. Entrectinib 5.3.8. Larotrectinib 5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033 6.3.1. Targeted therapy 6.3.2. Chemotherapy 6.3.3. Radiation therapy 6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End-user , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user , 2023 to 2033 7.3.1. Hospitals 7.3.2. Clinics 7.3.3. Specialized Cancer Treatment Centres 7.4. Y-o-Y Growth Trend Analysis By End-user , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By End-user , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Type 9.2.3. By Therapy 9.2.4. By End-user 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Type 9.3.3. By Therapy 9.3.4. By End-user 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Type 10.2.3. By Therapy 10.2.4. By End-user 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Type 10.3.3. By Therapy 10.3.4. By End-user 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Type 11.2.3. By Therapy 11.2.4. By End-user 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. By Therapy 11.3.4. By End-user 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Type 12.2.3. By Therapy 12.2.4. By End-user 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Type 12.3.3. By Therapy 12.3.4. By End-user 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Type 13.2.3. By Therapy 13.2.4. By End-user 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Type 13.3.3. By Therapy 13.3.4. By End-user 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Type 14.2.3. By Therapy 14.2.4. By End-user 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Type 14.3.3. By Therapy 14.3.4. By End-user 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Type 15.2.3. By Therapy 15.2.4. By End-user 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Type 15.3.3. By Therapy 15.3.4. By End-user 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Type 16.1.2.2. By Therapy 16.1.2.3. By End-user 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Type 16.2.2.2. By Therapy 16.2.2.3. By End-user 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Type 16.3.2.2. By Therapy 16.3.2.3. By End-user 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Type 16.4.2.2. By Therapy 16.4.2.3. By End-user 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Type 16.5.2.2. By Therapy 16.5.2.3. By End-user 16.6. United kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Type 16.6.2.2. By Therapy 16.6.2.3. By End-user 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Type 16.7.2.2. By Therapy 16.7.2.3. By End-user 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Type 16.8.2.2. By Therapy 16.8.2.3. By End-user 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Type 16.9.2.2. By Therapy 16.9.2.3. By End-user 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Type 16.10.2.2. By Therapy 16.10.2.3. By End-user 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Type 16.11.2.2. By Therapy 16.11.2.3. By End-user 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Type 16.12.2.2. By Therapy 16.12.2.3. By End-user 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Type 16.13.2.2. By Therapy 16.13.2.3. By End-user 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Type 16.14.2.2. By Therapy 16.14.2.3. By End-user 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Type 16.15.2.2. By Therapy 16.15.2.3. By End-user 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Type 16.16.2.2. By Therapy 16.16.2.3. By End-user 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Type 16.17.2.2. By Therapy 16.17.2.3. By End-user 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Type 16.18.2.2. By Therapy 16.18.2.3. By End-user 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Type 16.19.2.2. By Therapy 16.19.2.3. By End-user 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Type 16.20.2.2. By Therapy 16.20.2.3. By End-user 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Type 16.21.2.2. By Therapy 16.21.2.3. By End-user 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Type 17.3.3. By Therapy 17.3.4. By End-user 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Arog Pharmaceuticals 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Taiho Pharmaceutical 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Turning Point Therapeutics, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Cogent Biosciences, Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Plexxikon Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Theseus Pharmaceuticals 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Exelixis, Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Ipsen 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Bristol-Myers Squibb 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Takeda 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by End-user , 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Drug Type, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Therapy, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by End-user , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by End-user , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Type, 2023 to 2033 Figure 18: Global Market Attractiveness by Therapy, 2023 to 2033 Figure 19: Global Market Attractiveness by End-user , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by End-user , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Type, 2023 to 2033 Figure 38: North America Market Attractiveness by Therapy, 2023 to 2033 Figure 39: North America Market Attractiveness by End-user , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by End-user , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Type, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Therapy, 2023 to 2033 Figure 59: Latin America Market Attractiveness by End-user , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by End-user , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Type, 2023 to 2033 Figure 78: Europe Market Attractiveness by Therapy, 2023 to 2033 Figure 79: Europe Market Attractiveness by End-user , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by End-user , 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 97: South Asia Market Attractiveness by Drug Type, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Therapy, 2023 to 2033 Figure 99: South Asia Market Attractiveness by End-user , 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by End-user , 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 117: East Asia Market Attractiveness by Drug Type, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Therapy, 2023 to 2033 Figure 119: East Asia Market Attractiveness by End-user , 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by End-user , 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 137: Oceania Market Attractiveness by Drug Type, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Therapy, 2023 to 2033 Figure 139: Oceania Market Attractiveness by End-user , 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Drug Type, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Therapy, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by End-user , 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Drug Type, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Therapy, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Therapy, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by End-user , 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by End-user , 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by End-user , 2023 to 2033 Figure 157: MEA Market Attractiveness by Drug Type, 2023 to 2033 Figure 158: MEA Market Attractiveness by Therapy, 2023 to 2033 Figure 159: MEA Market Attractiveness by End-user , 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
